Drugs / ELVN-001
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06787144 | Jan 2025 → Jan 2028 expected | chronic myeloid leukemia | Enliven Therapeutics | Recruiting | No outcome recorded |
| Phase 1 | NCT05304377 | May 2022 → Dec 2027 expected | chronic myeloid leukemia | Enliven Therapeutics | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 11
| Date | Issuer | Release |
|---|---|---|
| 2026-06-11 | Enliven Therapeutics | Results Enliven Therapeutics Announces Updated Positive Phase 1 Clinical Data and Alignment with FDA on Key Phase 3 Trial Design Components enliventherapeutics.com ↗
The updated data from the ENABLE trial are very promising and encouraging. |
| 2026-05-12 | Enliven Therapeutics | Results Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML enliventherapeutics.com ↗ |
| 2026-01-08 | Enliven Therapeutics | Results Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones enliventherapeutics.com ↗
Cumulative major molecular response (MMR) rate of 69% by 24 weeks, with 53% of patients achieving MMR by 24 weeks in ongoing randomized Phase 1b cohorts |
| 2025-11-03 | Enliven Therapeutics | Results Enliven Therapeutics Announces Clinical Data in CML Patients with Atypical Fusion Transcripts at ASH 2025 Annual Meeting enliventherapeutics.com ↗
We observed encouraging anti-CML activity in the subset of patients with CML in the ENABLE study with atypical transcripts. |
| 2025-08-13 | Enliven Therapeutics | Results Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update enliventherapeutics.com ↗ |
| 2025-06-13 | Enliven Therapeutics | Results Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML at EHA 2025 Congress enliventherapeutics.com ↗
The data from ELVN-001 are encouraging, showing an efficacy, safety and tolerability profile that compare favorably to approved BCR::ABL1 inhibitors, despite being studied in a more heavily pretreated population. |
| 2025-05-14 | Enliven Therapeutics | Results Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update enliventherapeutics.com ↗
We are very pleased with the continued progress of ELVN-001 and the data that was just released in the EHA abstract. |
| 2025-05-14 | Enliven Therapeutics | Results Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML and Oral Presentation at the EHA 2025 Congress enliventherapeutics.com ↗ |
| 2024-09-28 | Enliven Therapeutics | Results Enliven Therapeutics Announces Positive Data Update from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia enliventherapeutics.com ↗
Additionally, ELVN-001 continues to be well-tolerated with no dose reductions and a median treatment duration of 20 weeks. |
| 2024-05-14 | Enliven Therapeutics | Results Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update enliventherapeutics.com ↗ |
| 2024-04-11 | Enliven Therapeutics | Results Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia enliventherapeutics.com ↗
Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced positive proof of concept data from the Phase 1 clinical trial evaluating ELVN-001 in patients with chronic myeloid leukemia (CML) who are relapsed, refractory, or intolerant to available tyrosine kinase inhibitors (TKIs) (NCT05304377). |
All press releases naming this drug 14 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ELVN-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06787144 ↗ |
| Route | Oral | “orally once or twice daily” NCT05304377 ↗ |